Glioblastoma in natalizumab‐treated multiple sclerosis patients
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Clinical and Translational Neurology"
DOI: 10.1002/acn3.428
Abstract: We present two natalizumab‐treated multiple sclerosis patients who developed glioblastoma multiforme (GBM) with variable outcomes. One patient had an isocitrate dehydrogenase (IDH)‐wildtype GBM with aggressive behavior, who declined treatment and died 13 weeks after symptoms… read more here.
Keywords: natalizumab treated; gbm; multiple sclerosis; sclerosis patients ... See more keywords
Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy
Sign Up to like & getrecommendations! Published in 2019 at "Journal of NeuroVirology"
DOI: 10.1007/s13365-019-00793-4
Abstract: Natalizumab is effective against relapsing-remitting multiple sclerosis (MS) but increases the risk of progressive multifocal leukoencephalopathy (PML), which is caused by the activation of the JCV polyomavirus. SF2/ASF (splicing factor2/alternative splicing factor) is a potent… read more here.
Keywords: natalizumab treated; progressive multifocal; multifocal leukoencephalopathy; splicing factor2 ... See more keywords
T Lymphocyte Serotonin 5-HT7 Receptor Is Dysregulated in Natalizumab-Treated Multiple Sclerosis Patients
Sign Up to like & getrecommendations! Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10102418
Abstract: Serotonin (5-HT) is known as a potent immune cell modulator in autoimmune diseases and should be protective in the pathogenesis of multiple sclerosis (MS). Nevertheless, there is limited knowledge about receptors involved in 5-HT effects… read more here.
Keywords: natalizumab treated; ht7 receptor; multiple sclerosis; ht7 ... See more keywords
JCPyV miR-J1-5p in Urine of Natalizumab-Treated Multiple Sclerosis Patients
Sign Up to like & getrecommendations! Published in 2021 at "Viruses"
DOI: 10.3390/v13030468
Abstract: The use of Natalizumab in Multiple Sclerosis (MS) can cause the reactivation of the polyomavirus JC (JCPyV); this may result in the development of progressive multifocal leukoencephalopathy (PML), a rare and usually lethal disease. JCPyV… read more here.
Keywords: natalizumab treated; jcpyv infection; jcpyv mir; multiple sclerosis ... See more keywords